A total of 81 test subjects aged 13 to 25 with risk factors for psychoses, attenuated symptoms for it, temporary psychoses or a “genetic risk“ took part in the study. 41 of them received Omega-3 fatty acid compounds over a period of three months, and 40 were given a placebo.
Three years ago, the authors, including Monika Schlögelhofer of the University Clinic for Children and Adolescent Psychiatry and Claudia Klier of the University Children’s Hospital in Vienna (Medical University of Vienna/Vienna General Hospital) showed the protective effect of Omega-3 fatty acids, monitoring test subjects over a period of twelve months. Now the data is available for an average period of 6.7 years- 71 of the original 81 test subjects could be observed over this time.
Accordingly, 9.89 percent of the group receiving Omega-3 compounds suffered from psychoses, compared to 40 percent in the placebo group. This comprises a difference of more than 30 percentage points.